IRIDEX Corporation (IRIX)

Currency in USD
1.170
+0.025(+2.18%)
Closed·
1.1700.000(0.00%)
·
Advertisement
IRIX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.1401.190
52 wk Range
0.8691.648
Key Statistics
Prev. Close
1.17
Open
1.18
Day's Range
1.14-1.19
52 wk Range
0.869-1.648
Volume
9.86K
Average Volume (3m)
252.65K
1-Year Change
28.5432%
Book Value / Share
-0.07
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IRIX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
2.750
Upside
+135.04%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year

IRIDEX Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 2.750
(+135.04% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Alliance Global Partners
Buy3.00+156.41%-New Coverage05/02/2026

IRIDEX Corporation Earnings Call Summary for Q1/2026

  • IRIDEX posted Q1 2026 EPS of -$0.03, beating forecast of -$0.05 by 40%; revenue missed at $11.8M vs. $13.17M expected (-10.4%)
  • Shares rose 2.46% aftermarket to $1.04 despite revenue shortfall, driven by investor confidence in cost management and strategic direction
  • Gross margin declined to 40% from 43% YoY due to higher manufacturing costs and supply chain disruptions; revenue remained flat vs. Q1 2025
  • Company expects positive operating cash flow for full year 2026; manufacturing transition to complete by 2027 to improve margins
  • Strategic partnerships including EyeProGPO aim to expand market access; challenges include supply chain issues and competitive pressure
Last Updated: 19/05/2026, 22:42
Read Full Transcript

Earnings

Latest Release
19/05/2026
EPS / Forecast
-0.03 / -0.05
Revenue / Forecast
11.8M / 13.17M
EPS Revisions
Last 90 days

IRIDEX (IRIX) Income Statement & Profits

Compare IRIX to Peers and Sector

Metrics to compare
IRIX
Peers
Sector
Relationship
P/E Ratio
−6.2x−2.8x−0.4x
PEG Ratio
−0.11−0.380.00
Price/Book
−16.1x1.3x2.6x
Price / LTM Sales
0.4x1.7x3.0x
Upside (Analyst Target)
135.0%62.5%51.3%
Fair Value Upside
Unlock10.7%7.3%Unlock

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. In addition, it offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform transscleral laser therapy; G-Probe and G-Probe Illuminate, which are used in procedures to treat uncontrolled and refractory glaucoma; and EndoProbe family of products that are used for endophotocoagulation. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics through direct and independent sales force in the United States, as well as through independent distributors internationally. It operates in the United States, Europe, the Middle East, Africa, the Asia/Pacific region, and the Americas. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
715.75K4.11%837.43K
Other Institutional Investors
5.83M33.49%6.82M
Public Companies & Retail Investors
10.86M62.40%12.71M
Total
17.41M100.00%20.37M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Topcon Corporation9.30%1,618,1221,893
Stanley Manne Trust6.16%1,072,2151,254

People Also Watch

0.3536
ONFO
+21.97%
4.80
KLC
+12.94%
11.000
ICCC
+9.45%
17.15
MNRO
+0.23%

FAQ

What Is the IRIDEX (NASDAQ: IRIX) Share Price Today?

The IRIDEX stock price today is 1.170 USD.

What Stock Exchange Does IRIDEX (IRIX) Trade On?

IRIDEX is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for IRIDEX?

The stock symbol (also called a 'ticker') for IRIDEX is "IRIX."

What Is the Current IRIDEX Market Capitalisation?

As of today, IRIDEX (NASDAQ: IRIX) market cap is 20.370M USD.

What Is IRIDEX's (IRIX) Earnings Per Share (TTM)?

The IRIDEX EPS is currently -0.192 (Trailing Twelve Months).

When Is the Next IRIDEX Earnings Date?

IRIDEX's next earnings report will be released on 06/08/2026.

Is IRIX a Buy or Sell From a Technical Analyst Perspective?

Based on today's IRIDEX moving averages and other technical indicators, the daily buy/sell signal for IRIX stock is Strong Buy.

How Many Times Has IRIDEX Stock Split?

IRIDEX has split 0 times. (See the IRIX stock split history page for full effective split date and price information.)

How Many Employees Does IRIDEX Have?

IRIDEX has 93 employees, based on their latest Companies House report.

What is the current trading status of IRIDEX (NASDAQ: IRIX)?

As of 02/07/2026, IRIDEX (IRIX) is trading at a share price of 1.170 USD, with a previous close of 1.170 USD. The stock has fluctuated within a day range of 1.140 USD to 1.190 USD, while its 52-week range spans from 0.869 USD to 1.648 USD.

What Is IRIDEX (IRIX) Price Target According to Analysts?

The average 12-month price target for IRIDEX is 2.750 USD, with a high estimate of 2.75 USD and a low estimate of 2.75 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +135.04% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.